Sinovac’s Covid-19 vaccine starts late stage trial in Indonesia
Beijing-based vaccine maker Sinovac Biotech has started Phase 3 trials for its Covid-19 vaccine candidate in Indonesia, Reuters reported.
The company is developing its candidate, called CoronaVac, with state-owned drug manufacturer Bio Farma and plans to test the vaccine’s effectiveness in about 1,620 patients in the country. The trial is expected to last six months and has recruited up to 1,215 subjects so far. Indonesia joins a growing list of countries that have granted permission for Covid-19 vaccine makers to test their vaccine candidates. Last month, Brazil and Bangladesh gave Sinovac the greenlight to run late-stage trials for CoronaVac.
The Chinese vaccine developer also released data from the vaccine’s Phase 2 trial last week, showing the vaccine appeared safe and elicited immune response in subjects.
Separately, state-owned vaccine rival Sinopharm published an interim analysis of its Phase 1 and 2 trial data for its vaccine candidate in JAMA. Researchers said patients who received the vaccine had a low rate of adverse reactions and demonstrated immunogenicity.
The company launched the vaccine’s Phase 3 trial in the United Arab Emirates last month.
The company is developing its candidate, called CoronaVac, with state-owned drug manufacturer Bio Farma and plans to test the vaccine’s effectiveness in about 1,620 patients in the country. The trial is expected to last six months and has recruited up to 1,215 subjects so far. Indonesia joins a growing list of countries that have granted permission for Covid-19 vaccine makers to test their vaccine candidates. Last month, Brazil and Bangladesh gave Sinovac the greenlight to run late-stage trials for CoronaVac.
The Chinese vaccine developer also released data from the vaccine’s Phase 2 trial last week, showing the vaccine appeared safe and elicited immune response in subjects.
Separately, state-owned vaccine rival Sinopharm published an interim analysis of its Phase 1 and 2 trial data for its vaccine candidate in JAMA. Researchers said patients who received the vaccine had a low rate of adverse reactions and demonstrated immunogenicity.
The company launched the vaccine’s Phase 3 trial in the United Arab Emirates last month.
.png)
No hay comentarios:
Publicar un comentario